Investing.com - Elevation Oncology (NASDAQ: ELEV) reported first quarter EPS of $-0.72, $0.16 worse than the analyst estimate of $-0.56. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Elevation Oncology's stock price closed at $3.67. It is up 270.71% in the last 3 months and up 0.82% in the last 12 months.
Elevation Oncology saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Elevation Oncology's stock price’s past reactions to earnings here.
According to InvestingPro, Elevation Oncology's Financial Health score is "weak performance".
Check out Elevation Oncology's recent earnings performance, and Elevation Oncology's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar